Welcome to our dedicated page for Artelo Biosciences SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artelo Biosciences, Inc. filings document a clinical-stage pharmaceutical issuer with securities listed on Nasdaq and a pipeline centered on lipid-signaling modulation. Registration statements and amendments describe securities offerings, delayed or continuous offering registration mechanics, common stock, warrants, pre-funded warrants and capital-structure terms.
Artelo's Form 8-K filings record material events including Nasdaq continued-listing compliance, annual-meeting matters, private-placement activity, material agreements, and clinical or regulatory disclosures for programs such as ART27.13 and ART26.12. The filings connect formal governance and financing records with updates on the company's drug-development strategy and intellectual-property activity.
ARTL terminates its At-The-Market equity offering agreement effective May 18, 2026. The company had an ATM capacity of $6,500,000 and reports aggregate sales of 50,858 shares for gross proceeds of $451,526.95. The prospectus supplement ends the continuous offering under the ATM Prospectus.
The Sales Agreement with R.F. Lafferty & Co., Inc. was terminated by notice on May 11, 2026, effective May 18, 2026. The Common Stock trades on Nasdaq under the symbol ARTL; the last reported sales price on May 15, 2026 was $1.84.
Artelo Biosciences, Inc. has elected to terminate its At-The-Market Offering Agreement with R.F. Lafferty & Co., Inc., a program that allowed the company to sell common stock over time. The termination notice was given on May 11, 2026 and becomes effective on May 18, 2026.
Under the agreement, Artelo could offer up to $6,500,000 of common stock in an at-the-market equity program. Through May 11, 2026, it sold 50,858 shares of common stock, generating $451,526.95 in gross proceeds before ending the arrangement.
Artelo Biosciences, Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 235,823 shares of common stock, representing 9.99% of the class. The filing states Armistice Capital exercises voting and investment power over the shares held by Armistice Capital Master Fund Ltd.
The Schedule 13G identifies Armistice Capital as the investment manager and Mr. Boyd as its managing member; the Master Fund is the direct holder and retains the right to receive proceeds or dividends.
Artelo Biosciences reported a net loss of $2.96M for the three months ended March 31, 2026, compared with $2.37M a year earlier, as general and administrative costs rose and research and development spending shifted lower. Operating expenses reached $2.69M, driven mainly by higher professional fees and stock-based compensation. Cash and cash equivalents jumped to $10.27M from $0.60M at year-end, largely due to a March 2026 private placement that generated gross proceeds of $10.997M (net $10.03M) through common shares and a large package of pre-funded and common warrants. The company also issued three convertible notes with variable conversion features, recognized a derivative liability of $0.58M, and recorded a day-one loss of $0.46M on one note. Despite the improved liquidity, management states that recurring losses and funding needs raise substantial doubt about Artelo’s ability to continue as a going concern within one year.
Artelo Biosciences, Inc. filed Amendment No. 1 to its Registration Statement (File No. 333-295537) to furnish Exhibit 4.3 and to update Part II disclosures. The amendment includes an estimated SEC registration fee of $788.05 and states a prior registration fee of $7,636.16 associated with $69,293,654.25 of unsold securities that will be carried forward pursuant to Rule 415(a)(6).
The filing restates indemnification provisions under Nevada law, notes indemnification limits for Securities Act liabilities, lists exhibits (including a Form of Indenture filed herewith), and includes customary undertakings regarding post-effective amendments and prospectus updates.
Artelo Biosciences, Inc. is filing a shelf registration to offer up to $75,000,000 of securities, which may include common stock, preferred stock, debt securities, warrants and units. The registration also includes $69,293,654.25 of unsold securities carried forward from a prior registration under Rule 415(a)(6).
The shelf permits offers from time to time; specific terms, pricing and distribution methods will be provided in prospectus supplements. Use of proceeds is generally for working capital and general corporate purposes, with any specific allocation set forth in future prospectus supplements.
Artelo Biosciences is registering up to 9,820,294 shares of Common Stock for resale. The shares consist of 81,000 issued shares, up to 3,107,407 shares issuable on Pre-Funded Warrants, up to 6,376,814 shares issuable on Common Warrants and up to 255,073 shares issuable on Placement Agent Warrants.
The Company is not selling any shares here and will not receive proceeds from resale by the Selling Stockholders; however, Artelo may receive up to $21,508,908.56 in gross proceeds if the Warrants and Placement Agent Warrants are exercised for cash. The prospectus discloses Beneficial Ownership Limitation provisions (4.99% or 9.99% election) and cashless-exercise conditions for certain Warrants.
Artelo Biosciences, Inc. is registering 9,820,294 shares of common stock for resale by existing investors under a Form S-1. The shares relate to an March 27, 2026 private placement of 81,000 shares, 3,107,407 pre-funded warrant shares, 6,376,814 common warrant shares and 255,073 placement agent warrant shares.
Artelo will not receive proceeds from stockholder resales but may receive up to $21.5 million in gross proceeds if the warrants are exercised for cash, which it expects to use for working capital, general corporate purposes and repayment of bridge debt. Its stock trades on Nasdaq as “ARTL,” with a $6.61 closing price on April 6, 2026. The prospectus highlights significant dilution and resale overhang risks for existing holders.